Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

1.2K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
1.2K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

727
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
727
Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy01:26

Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy

364
This lesson explores three gastrointestinal imaging techniques: radionuclide testing, colonic transit studies, and virtual colonoscopy.
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
364
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

532
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
532
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

284
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
284

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.

JCO precision oncology·2026
Same author

Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers.

Journal of neuroendocrinology·2026
Same author

Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease.

Journal of neuroendocrinology·2026
Same author

Small Cell and Large Cell Neuroendocrine Carcinoma of the Colon and Rectum: Population-Based Analysis of Incidence, Survival, and Site-Specific Outcomes.

Cancers·2026
Same author

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Clinicopathologic, molecular, and treatment features of metastatic and distantly recurrent extramammary Paget disease: Mayo clinic experience.

The oncologist·2026

Video Experimental Relacionado

Updated: Jan 13, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.4K

Concentraciones elevadas de péptido intestinal vasoactivo predicen mal el VIPoma

Jack Korleski1, Luis E Ospina Velasquez2, Joshua Bornhorst3

  • 1Department of Internal Medicine, Mayo Clinic, Rochester MN United States.

Endocrine-related cancer
|January 7, 2026
PubMed
Resumen

El diagnóstico del VIPoma, un raro tumor neuroendocrino, es difícil. Este estudio encontró que, si bien pueden ocurrir niveles elevados de péptido intestinal vasoactivo (VIP), un umbral de 442 pg/mL es óptimo para predecir el VIPoma, evitando pruebas innecesarias.

Palabras clave:
exactitud diagnósticadiarrea crónica

Más Videos Relacionados

Author Spotlight: Gut Microbiome-Lung Tissue Communication Through Short-Chain Fatty Acid Analysis
04:09

Author Spotlight: Gut Microbiome-Lung Tissue Communication Through Short-Chain Fatty Acid Analysis

Published on: June 21, 2024

2.6K
Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

15.0K

Videos de Experimentos Relacionados

Last Updated: Jan 13, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.4K
Author Spotlight: Gut Microbiome-Lung Tissue Communication Through Short-Chain Fatty Acid Analysis
04:09

Author Spotlight: Gut Microbiome-Lung Tissue Communication Through Short-Chain Fatty Acid Analysis

Published on: June 21, 2024

2.6K
Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

15.0K

Área de la Ciencia:

  • Endocrinología
  • Oncología
  • Gastroenterología

Sus antecedentes:

  • El VIPoma es un raro tumor neuroendocrino (NET) con desafíos diagnósticos.
  • Los niveles elevados de péptido intestinal vasoactivo (VIP) son característicos pero carecen de un umbral diagnóstico definido.
  • La interpretación precisa de los niveles de VIP es crucial para el diagnóstico de VIPoma.

Objetivo del estudio:

  • Determinar el umbral óptimo para las concentraciones plasmáticas de VIP en el diagnóstico de VIPoma.
  • Comparar los niveles de VIP en pacientes con y sin VIPoma.
  • Evaluar la utilidad diagnóstica de la prueba de VIP en una población de una sola institución.

Principales métodos:

  • Revisión retrospectiva de los resultados de las pruebas de VIP (2011-2023) para pacientes con niveles de VIP > 75 pg/mL.
  • Comparación de las concentraciones plasmáticas de VIP entre cohortes con VIPoma confirmado y sin VIPoma.
  • Análisis estadístico para determinar el umbral óptimo de VIP y su valor predictivo.

Principales resultados:

  • Nueve VIPomas fueron diagnosticados entre 76 pacientes elegibles; todos tenían diarrea crónica.
  • La concentración media de VIP fue mayor en pacientes con VIPoma (508 pg/mL) frente a los no VIPoma (223 pg/mL), pero no fue estadísticamente significativa (p=0.31).
  • Se identificó un umbral óptimo de VIP de 442 pg/mL (OR: 11,96, p=0,01), con razones de probabilidad significativas a partir de 200 pg/mL. El valor predictivo positivo a 75 pg/mL fue solo del 12%.

Conclusiones:

  • Las concentraciones elevadas de VIP por sí solas no son altamente predictivas de VIPoma.
  • La mayoría de los pacientes con niveles elevados de VIP no tienen VIPoma.
  • Se recomienda un uso juicioso de las pruebas de VIP en escenarios clínicos específicos para prevenir investigaciones innecesarias.